Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas Smith

Showing results (151-160 of 303) with videos related to

Pageof 31
Sort By:
Blood|January 27, 2005
Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasiaDamiano Rondelli, Giovanni Barosi, Andrea Bacigalupo, et al.
Frontiers in Oncology|November 16, 2020
A Phase 1 Study of IRX195183, a RARα-Selective CYP26 Resistant Retinoid, in Patients With Relapsed or Refractory AMLAlexander J Ambinder, Kelly Norsworthy, Daniela Hernandez, et al.
Hematological Oncology|January 19, 2022
Venetoclax exposure-efficacy and exposure-safety relationships in patients with treatment-naïve acute myeloid leukemia who are ineligible for intensive chemotherapyDeanna Brackman, Doerthe Eckert, Rajeev Menon, et al.
Leukemia & Lymphoma|July 21, 2021
A phase II study of azacitidine in combination with granulocyte-macrophage colony-stimulating factor as maintenance treatment, after allogeneic blood or marrow transplantation in patients with poor-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)Jonathan A Webster, Meera Yogarajah, Marianna Zahurak, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 18, 2011
Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institutionAmy E DeZern, Anthony Sung, Sharon Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2007
Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemiaJudith E Karp, B Douglas Smith, Mark J Levis, et al.
Epigenetics|July 31, 2010
Epigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemiaElizabeth A Griffiths, Steven D Gore, Craig M Hooker, et al.
Blood|October 12, 2010
Early lymphocyte recovery after intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cellsChristopher G Kanakry, Allan D Hess, Christopher D Gocke, et al.
Blood|June 15, 2007
A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemiasJudith E Karp, Rebecca M Ricklis, Kumudha Balakrishnan, et al.
Environmental Science & Technology|February 17, 2010
Arsenic mobilization in a seawater inundated acid sulfate soilScott G Johnston, Annabelle F Keene, Edward D Burton, et al.
Pageof 31

Showing results (151-160 of 303) with videos related to

Sort By:
Pageof 31
Blood|January 27, 2005
Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasiaDamiano Rondelli, Giovanni Barosi, Andrea Bacigalupo, et al.
Frontiers in Oncology|November 16, 2020
A Phase 1 Study of IRX195183, a RARα-Selective CYP26 Resistant Retinoid, in Patients With Relapsed or Refractory AMLAlexander J Ambinder, Kelly Norsworthy, Daniela Hernandez, et al.
Hematological Oncology|January 19, 2022
Venetoclax exposure-efficacy and exposure-safety relationships in patients with treatment-naïve acute myeloid leukemia who are ineligible for intensive chemotherapyDeanna Brackman, Doerthe Eckert, Rajeev Menon, et al.
Leukemia & Lymphoma|July 21, 2021
A phase II study of azacitidine in combination with granulocyte-macrophage colony-stimulating factor as maintenance treatment, after allogeneic blood or marrow transplantation in patients with poor-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)Jonathan A Webster, Meera Yogarajah, Marianna Zahurak, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 18, 2011
Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institutionAmy E DeZern, Anthony Sung, Sharon Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2007
Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemiaJudith E Karp, B Douglas Smith, Mark J Levis, et al.
Epigenetics|July 31, 2010
Epigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemiaElizabeth A Griffiths, Steven D Gore, Craig M Hooker, et al.
Blood|October 12, 2010
Early lymphocyte recovery after intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cellsChristopher G Kanakry, Allan D Hess, Christopher D Gocke, et al.
Blood|June 15, 2007
A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemiasJudith E Karp, Rebecca M Ricklis, Kumudha Balakrishnan, et al.
Environmental Science & Technology|February 17, 2010
Arsenic mobilization in a seawater inundated acid sulfate soilScott G Johnston, Annabelle F Keene, Edward D Burton, et al.
Pageof 31